Category: Biotech

November 15, 2022

Two months ago, biotechnology startup Good Therapeutics struck it big. A cancer immunotherapy the company was working on drew such interest from Roche that the Swiss pharmaceutical giant paid $250 million, far more than the $30 million the startup had […]

October 20, 2022

Plunging stock prices shook the biotech sector this year. Young companies attempting to go public found little appetite for the sky-high valuations that were common in 2020 and 2021’s bull run of IPOs. Some investors described that period as resulting […]

October 17, 2022

Demand for nanoparticles in the biopharmaceutical industry is on the rise. Production of these tiny particles, which can protect and deliver medicines and vaccines where they need to go in the body, has been increasing since 1989. Over the last […]

September 26, 2022

Prime’s filing represents a key test for biotech initial public offerings, which are showing some early signs of life after a prolonged slowdown. Twelve days ago, autoimmune drug developer Third Harmonic Bio provided the sector with a lift. By raising […]

September 15, 2022

This week has been one of the most exciting that the biotechnology community has seen for some time. Plans that have been in the making for a decade are finally being brought to fruition by actions taken by the Biden […]

August 5, 2022

The pace of innovation in biopharma has rocketed over the last two years, with vaccines, new antivirals, and therapies delivered at an unprecedented pace. This has been a tough but ground-breaking period, but with this rapid rise in innovation comes […]

August 4, 2022

Amgen plans to acquire a fellow Californian biotechnology company, ChemoCentryx, for $3.7 billion in a deal meant to deepen its pool of medicines targeting inflammation and the kidneys. The companies expect their deal, announced Thursday, to close sometime between October […]

August 2, 2022

Venture capital firms have poured tens of billions of dollars into new drug startups over the past several years, greatly expanding the ranks of biotechnology companies both private and public. But some argue there’s still room for more. Specifically, there’s […]

July 26, 2022

Agios Pharmaceuticals needed money. It was 2010 and Agios, like many other biotechnology startups then, was trying to survive following a global recession. Venture capital was contracting, leaving emerging companies with fewer financing options. Initial public offerings, a main source of […]

July 26, 2022

ExcellGene SA, privately held and founded 2001, has announced its role in the recently approved consortium funding through the Coalition for Epidemic Preparedness Innovations (CEPI), a global partnership of public, private, philanthropic and civil society organizations founded to develop vaccines […]

July 15, 2022

The PureTech group company – which scored the first FDA and EMA approvals for a DTx for attention-deficit hyperactivity disorder (ADHD) – is developing AKL-T01 to tackle cognitive impairments that can affect people with SLE. Cognitive dysfunction occurs in between […]

July 13, 2022

Bicycle’s bicyclic peptide drug discovery platform is designed to produce drug candidates that have targeting properties like antibodies but are much smaller molecules, making manufacturing and dosing easier. The time the peptides stay in the body can also be fine-tuned, […]

July 13, 2022

“Your primary endpoint is now down to a subjective measure in different trial centres, perhaps done by different people with different subjectivity,” says David van Zuydam, CEO of Head Therapeutics. “And now we’re going to determine whether this drug is […]

June 6, 2022

After nearly eight years, Yumanity’s time as an independent company appears close to an end. The biotech was established in late 2014 — the creation of Tony Coles, Susan Lindquist and Ken Rhodes, each well-known in the pharmaceutical industry for […]

June 6, 2022

Athersys’s research efforts are centered around a cell therapy platform it has been studying across a range of conditions, including stroke, respiratory distress and heart attack. In stroke, Athersys is working with Japan’s Healios, which tested Athersys’ cell therapy as […]

May 25, 2022

Established in 2006, Genocea originally focused on vaccines. It went public in 2014 and at one point saw its shares soar above $150. But in 2017, just as the company was poised to begin a Phase 3 trial of an […]

May 24, 2022

BridgeBio Pharma is digging in for a prolonged bear market. Since suffering a phase 3 flop late last year, the biotech has taken a series of steps to extend its cash runway, reflecting its CEO’s belief that markets could “stay […]

May 23, 2022

Holding company Innoviva is acquiring late-stage antibiotic biotech Entasis Therapeutics, a 2015 AstraZeneca spin-out that just posted phase 3 results worthy of an FDA filing last year. Innoviva already owns about 60% of Entasis’ outstanding shares. Under the new definitive […]

May 19, 2022

A common infection, RSV results in only mild, cold-like symptoms in most people. Yet the disease causes 58,000 hospitalizations a year in children under 5 and 177,000 in the elderly. After decades of disappointment, vaccine makers may finally be close […]

May 9, 2022

ALSA Ventures, a London based European biotech investment firm, and Lonza, a global development and manufacturing partner to the pharma, biotech and nutrition industries, have entered a collaboration agreement to help develop and manufacture biologics and small molecule drug candidates […]